Recent News

• 12.11.2025 - Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
• 12.05.2025 - Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
• 12.04.2025 - Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
• 11.06.2025 - Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
• 10.31.2025 - Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
• 10.30.2025 - Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
• 09.10.2025 - Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Recent Filings

• 12.05.2025 - EX-99.1 EX-99.1
• 12.05.2025 - 8-K Current report
• 12.04.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.04.2025 - 8-K Current report
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 10.31.2025 - EX-99.1 EX-99.1
• 10.31.2025 - 8-K Current report